Polymyositis: Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)Dermatomyositis: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)Myositis: Inflammation of a muscle or muscle tissue.Histidine-tRNA Ligase: An enzyme that activates histidine with its specific transfer RNA. EC 6.1.1.21.Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.Myositis, Inclusion Body: Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Muscular Diseases: Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Paraneoplastic Syndromes: In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.Creatine Kinase: A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins.Muscles: Contractile tissue that produces movement in animals.Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.Muscle, Skeletal: A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.MyoglobinuriaNervous System Autoimmune Disease, Experimental: Experimental animal models for human AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM. They include GUILLAIN-BARRE SYNDROME (see NEURITIS, AUTOIMMUNE, EXPERIMENTAL); MYASTHENIA GRAVIS (see MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL); and MULTIPLE SCLEROSIS (see ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL).Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.Mediastinal Emphysema: Presence of air in the mediastinal tissues due to leakage of air from the tracheobronchial tree, usually as a result of trauma.Antibodies, Antinuclear: Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)Muscular Dystrophies: A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Mixed Connective Tissue Disease: A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence.Pharyngectomy: Surgical removal of a part of the pharynx. (Dorland, 28th ed)Muscle Strength Dynamometer: A device that measures MUSCLE STRENGTH during muscle contraction, such as gripping, pushing, and pulling. It is used to evaluate the health status of muscle in sports medicine or physical therapy.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Posterior Leukoencephalopathy Syndrome: A condition that is characterized by HEADACHE; SEIZURES; and visual loss with edema in the posterior aspects of the CEREBRAL HEMISPHERES, such as the BRAIN STEM. Generally, lesions involve the white matter (nerve fibers) but occasionally the grey matter (nerve cell bodies).Hypertensive Encephalopathy: Brain dysfunction or damage resulting from sustained MALIGNANT HYPERTENSION. When BLOOD PRESSURE exceeds the limits of cerebral autoregulation, cerebral blood flow is impaired (BRAIN ISCHEMIA). Clinical manifestations include HEADACHE; NAUSEA; VOMITING; SEIZURES; altered mental status (in some cases progressing to COMA); PAPILLEDEMA; and RETINAL HEMORRHAGE.Eclampsia: Onset of HYPERREFLEXIA; SEIZURES; or COMA in a previously diagnosed pre-eclamptic patient (PRE-ECLAMPSIA).Blindness, Cortical: Total loss of vision in all or part of the visual field due to bilateral OCCIPITAL LOBE (i.e., VISUAL CORTEX) damage or dysfunction. Anton syndrome is characterized by the psychic denial of true, organic cortical blindness. (Adams et al., Principles of Neurology, 6th ed, p460)Desonide: A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES.Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.High-Throughput Nucleotide Sequencing: Techniques of nucleotide sequence analysis that increase the range, complexity, sensitivity, and accuracy of results by greatly increasing the scale of operations and thus the number of nucleotides, and the number of copies of each nucleotide sequenced. The sequencing may be done by analysis of the synthesis or ligation products, hybridization to preexisting sequences, etc.Sequence Analysis, DNA: A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis.Transcriptome: The pattern of GENE EXPRESSION at the level of genetic transcription in a specific organism or under specific circumstances in specific cells.Dermatomycoses: Superficial infections of the skin or its appendages by any of various fungi.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Polyglutamic Acid: A peptide that is a homopolymer of glutamic acid.Antirheumatic Agents: Drugs that are used to treat RHEUMATOID ARTHRITIS.Folic Acid Antagonists: Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033)Tetrahydrofolate Dehydrogenase: An enzyme of the oxidoreductase class that catalyzes the reaction 7,8-dihyrofolate and NADPH to yield 5,6,7,8-tetrahydrofolate and NADPH+, producing reduced folate for amino acid metabolism, purine ring synthesis, and the formation of deoxythymidine monophosphate. Methotrexate and other folic acid antagonists used as chemotherapeutic drugs act by inhibiting this enzyme. (Dorland, 27th ed) EC 1.5.1.3.Professional Role: The expected function of a member of a particular profession.United StatesNevus, Sebaceous of Jadassohn: A syndrome characterized by lesions occurring on the face, scalp, or neck which consist of congenital hypoplastic malformations of cutaneous structures and which over time undergo verrucous hyperplasia. Additionally it is associated with neurological symptoms and skeletal, ophthalmological, urogenital, and cardiovascular abnormalities.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Information Centers: Facilities for collecting and organizing information. They may be specialized by subject field, type of source material, persons served, location, or type of services.Rare Diseases: A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment.National Health Planning Information Center (U.S.): A center in the HEALTH RESOURCES ADMINISTRATION Division of Planning Methods and Technology which provides access to current information on health planning and resources development.Poison Control Centers: Facilities which provide information concerning poisons and treatment of poisoning in emergencies.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.
Safety of a home exercise programme in patients with polymyositis and dermatomyositis: A pilot study. Rheumatology. 38, 608-611 ... Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. British ... In 2001, 22 patients were placed on a three-week physical therapy and exercise program, and found that creatine kinase levels ... exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. ...
Patients have symptoms of both systemic scleroderma and/or polymyositis and dermatomyositis. Scleroderma: a group of rare ... Treatment of these patients is therefore strongly dependent on the exact symptoms with which a patient reports to a physician ... Patients with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is ... Patient should seek a physician for skin tests. Typically, after a consultation with rheumatologist, the disease will be ...
"Polymyositis and Dermatomyositis: Autoimmune Disorders of Connective Tissue: Merck Manual Home Health Handbook". Ghirardello A ... Albert ML, Austin LM, Darnell RB (2000). "Detection and treatment of activated T cells in the cerebrospinal fluid of patients ... I. A clinical analysis of 55 anti-Yo antibody-positive patients". Neurology. 42 (10): 1931-7. doi:10.1212/wnl.42.10.1931. PMID ... Boulassel MR, Deggouj N, Tomasi JP, Gersdorff M (January 2001). "Inner ear autoantibodies and their targets in patients with ...
The hook connects to the ankle cuff and lifts the shoe up when the patient walks. Yoga foot drop Toe walking Polymyositis ... Drop foot TC: Terminal contact that is observed in patients that have drop foot is quite different. Since patients tend to have ... Patients with painful disorders of sensation (dysesthesia) of the soles of the feet may have a similar gait but do not have ... Because of the extreme pain evoked by even the slightest pressure on the feet, the patient walks as if walking barefoot on hot ...
... polymyositis, or dermatomyositis alone. As the autobodies are found mainly in patients that have characteristics of several ... "PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome". Arthritis & Rheumatism. 50 ( ... an autoimmune disease in which patients have symptoms from both scleroderma and either polymyositis or dermatomyositis. ... "C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome". Arthritis & Rheumatism. 56 ...
"C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome". Arthritis Rheum. 56 (7): ...
High troponin T levels have also been reported in patients with inflammatory muscle diseases such as polymyositis or ... April 2001). "Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis ... and troponin screening is appropriate in these patients. Some patients with dissection of the ascending aorta have elevated ... According to the latest data cTnI is released in the blood stream of the patient in the form of binary complex with TnC or ...
2004). "PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome". Arthritis Rheum. 50 ... the protein product of which is part of the exosome complex and is an autoantigen is patients with certain auto immune diseases ... "Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD ...
2004). "PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome". Arthritis Rheum. 50 ... the protein product of which is part of the exosome complex and is an autoantigen is patients with certain auto immune diseases ... "Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete ...
... dermatomyositis and polymyositis". Int. J. Cancer. 116 (6): 925-33. doi:10.1002/ijc.21118. PMID 15856462. Rual JF, Venkatesan K ... "Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, ...
Muscle biopsies are taken to aid in the diagnosis of muscle diseases (such as polymyositis, mitochondrial myopathy, etc.). ... Peripheral nerve is assessed to help work up patients with suspected peripheral neuropathies secondary to such conditions as ...
... levels were significantly higher in patients with OSA compared to obese control subjects. Patients with OSA have higher plasma ... Scleroderma, polymyositis, and dermatomyositis elicit little or no CRP response. CRP levels also tend not to be elevated in SLE ... CRP was so named because it was first identified as a substance in the serum of patients with acute inflammation that reacted ... It has been hypothesized that patients with high CRP levels might benefit from use of statins. This is based on the JUPITER ...
A comparison between adult patients and children". Digestion. 15 (4): 260-70. doi:10.1159/000198011. PMID 863130.. ... In inclusion body myositis, polymyositis and dermatomyositis[edit]. HLA-DR3 has been consistently observed at high frequencies ... In one study 65% of patients with end stage autoimmune hepatitis had coeliac associated HLA-DQ (DQ2, DQ8), of these half had ... In systemic lupus erythematosus (SLE) patients HLA DR3-DQ2.5-C4AQ0, which was strongly associated with SLE (odds ratio [OR] 2.8 ...
... an autoimmune disease in which patients have symptoms from both scleroderma and either polymyositis or dermatomyositis.[40] ... "PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome". Arthritis & Rheumatism. 50 ( ... "C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome". Arthritis & Rheumatism. 56 ... but they can also be detected in patients suffering from either scleroderma, polymyositis, or dermatomyositis alone.[46] ...
... is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets ... "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017. " ...
The most common antibody is "Anti-Jo-1" named after John P, a patient with polymyositis and interstitial lung disease detected ... For patients with pulmonary involvement, the most serious complication of this syndrome is pulmonary fibrosis and subsequent ... This anti-histidyl tRNA Synthetase antibody is commonly seen in patients with pulmonary manifestations of the syndrome. The ... Anti-synthetase syndrome is a autoimmune disease associated with interstitial lung disease, dermatomyositis, and polymyositis. ...
Patients with dermatomyositis and polymyositis have increased IFN serum levels which in some studies correlate with disease ... MS patients have lower levels of circulating type I interferon compared to patients with other autoimmune diseases. However, a ... Furthermore, patients with non-autoimmune diseases treated with IFN-α can develop a "lupus-like" syndrome, including ... Also, studies have suggested a genetic or heritable component to the high type I IFN observed in myositis patients, similar to ...
It may have different root causes unrelated to either polymyositis or sIBM. IBMmyositis.com http://patient.info/doctor/ ... IBM is often confused with (misdiagnosed as) polymyositis. Polymyositis that does not respond to treatment is likely IBM. ... Patients with sIBM usually eventually need to resort to a cane or a walker and in most cases, a wheelchair eventually becomes a ... Patients may become unable to perform activities of daily living and most require assistive devices within 5 to 10 years of ...
... recognized by autoantibodies from patients with scleroderma-polymyositis overlap syndrome". Proc. Natl. Acad. Sci. U.S.A. 87 (5 ... Ku was originally identified when patients with systemic lupus erythematosus were found to have high levels of autoantibodies ... A rare microsatellite polymorphism in this gene is associated with cancer in patients of varying radiosensitivity. A deficiency ...
Human leukocyte antigen class II genes are more frequent in patients with Kikuchi disease, suggesting a genetic predisposition ... Other autoimmune conditions and manifestations such as antiphospholipid syndrome, polymyositis, systemic juvenile idiopathic ... a self-limiting illness which has symptoms which may overlap with Hodgkin's lymphoma leading to misdiagnosis in some patients. ...
"Simvastatin 80 mg should not be started in new patients, including patients already taking lower doses of the drug," the agency ... M33.2) Polymyositis produces muscle weaknesss. It can often be treated by drugs like corticosteroids or immunosuppressants. ... Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies ... The FDA drug safety communication stated that physicians should limit using the 80-mg dose unless the patient has already been ...
The study of masticatory force in different types of patients such as patients with polymyositis and dermatomyositis shows that ...
There are some concerns with the use of anti-TNF agents in patients with systemic autoimmune diseases due to the risk of ... Polymyositis, Dermatomyositis, Rheumatoid arthritis (RA) Sjögren's syndrome Eosinophilic granulomatosis with polyangiitis (EGPA ... Diagnosis depends on which diseases the patient shows symptoms and has positive antibodies for in their lab serology. In ...
... in patients who have had strokes, and in patients who are admitted to acute care hospitals or chronic care facilities. ... Esophageal varices Benign strictures Achalasia Esophagial diverticula Scleroderma Diffuse esophageal spasm Polymyositis Webs ... patient complaint of swallowing difficulty). When asked where the food is getting stuck, patients will often point to the ... Some patients have limited awareness of their dysphagia, so lack of the symptom does not exclude an underlying disease. When ...
Polymyositis and dermatomyositis are first treated with high doses of a corticosteroids myopathy (muscle disease) myalgia ( ... and Understanding Association The Johns Hopkins Myositis Center University of Washington Department of Orthopaedics Patient ... inflammatory myopathies dermatomyositis juvenile dermatomyositis polymyositis inclusion body myositis pyomyositis Elevation of ...
UK Primary Immunodeficiency Patient Support Association (UKPIPS - UK Primary Immunodeficiency Patient Support Association) ... polymyositis, pyogenic infections) C3 deficiency (recurrent pyogenic infections) C5 deficiency (Neisserial infections, SLE) C6 ... "Definitive" diagnosis is made when it is likely that in 20 years, the patient has a >98% chance of the same diagnosis being ... "Probable" diagnosis is made when no genetic diagnosis can be made, but the patient has all other characteristics of a ...
... general Encephalopathy Care and treatment Immunotherapy Patient compliance Scleroderma (Disease) Systemic scleroderma ... Recurring posterior reversible encephalopathy syndrome in a patient with polymyositis/systemic sclerosis overlap syndrome ... However, there are few reports of PRES in patients with SSc. Here we present a case with polymyositis (PM)/SSc overlap syndrome ... MLA style: "Recurring posterior reversible encephalopathy syndrome in a patient with polymyositis/systemic sclerosis overlap ...
Among patients with MCTD, patterns of organ targeting have been reported that suggest disease subtypes. Some patients have more ... Polymyositis is a rare autoimmune disease characterized by inflammatory degenerative changes in the muscle fibers and the ... Some patients have more myositis manifestations and have higher risk for interstitial lung disease. Some patients with more ... Cohort studies of MCTD patients with pulmonary hypertension or other lung disease have suggested that these patients may be ...
Some patients with ILD may have features of a CTD, but not meet all of the criteria necessary to diagnosis a specific ... Polymyositis. *Dermatomyositis. *Mixed connective tissue disease. *Undifferentiated connective tissue disease. CTD-ILD causes ... These patients may be at risk for developing a specific autoimmune disease in the future and should be evaluated by a ...
Polymyositis and Rheumatoid Arthritis (RA), in association with the presence of high titer of autoantibody to U1 ... among 345 patients with focal AT who underwent radiofrequency ablation only 4% of patients (n=14) had preexisting structural ... The patient was discharged well the next day. Previous medications (digoxin, bisoprolol, and pradaxa) was stopped and she was ... In conclusion, a case of focal AT itself is uncommon, and for it to occur in a patient with underlying mixed connective tissue ...
A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis ... Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global ... Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and ... Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. ...
We describe a case of a female patient who developed significant respiratory dysfunction as the principal clinical sign. Video- ... polymyositis/dermatomyositis, and Sjögrens syndrome [1-9]. UCTD can evolve in these patients over time. ... In particular, UCTD was detected in 22% of NSIP patients [13].. In conclusion, we have described a case of a patient with UCTD ... Kinder et al. recently showed that the majority of patients (88%) who met the UCTD criteria had distinct radiological and ...
YKL-40 seen as promising biomarker for polymyositis, dermatomyositis-associated interstitial lung disease ... Systemic sclerosis: Choosing patients wisely when treating interstitial lung disease *Health Tip: Worried About Lung Disease? ...
We know many patients feel utterly alone and are frequently treated as if they have psychological issues, rather than an ... Scleroderma and Polymyositis. Two additional diseases, Rheumatoid Arthritis and Sjogrens Disease, may also contribute their ... Raynauds Phenomenon is often the first symptom and precedes the rest by many months or years, occurring in 85% of patients ... Pulmonary Hypertension (High blood pressure in the pulmonary arteries) is the main cause of death in MCTD patients ...
Doctors suspect mixed connective tissue disease when symptoms of lupus, systemic sclerosis, and polymyositis (see Polymyositis ... Every 1 in 3 Psoriasis Patients Develops Arthritis. Medically reviewed by Dr. Joseph Tan ... scleroderma and polymyositis. For this reason, mixed connective tissue disease is sometimes referred to as an overlap disease. ...
Investigating Genes in Patients With Polymyositis and Dermatomyositis (AOMIC). The safety and scientific validity of this study ... Patients below the age of 18 years. *Patients with myositis secondary to alcohol or drug abuse, non abusive drug ingestion (e.g ... Patients with myositis following a recent viral illnesses.. *Patients unable to consent for themselves due to diminished mental ... patients with PM, DM or IBM, will be asked to give 20 mls of blood. These blood samples, along with the patients clinical ...
Assessment of myositis patients has relied on symptoms, strength testing, and serum muscle enzyme activity. Recently, ... RESULTS: The mean peak VO2 in patients with dermatomyositis/polymyositis was 15.3 mL/min/kg (SD = 5.8) and in the healthy ... PATIENTS: Twenty-two subjects (8 outpatients with chronic dermatomyositis and 3 outpatients with chronic polymyositis, and 11 ... Aerobic exercise testing may be a useful assessment parameter in selected patients with dermatomyositis/ polymyositis.. ...
The concentration of soluble interleukin 2 receptor was determined in serum samples from 19 patients with polymyositis/ ... The concentration of soluble interleukin 2 receptor in serum samples from patients with polymyositis/dermatomyositis was higher ...
As cardiac involvement in polymyositis may become overt if the disease persists for many years, patients refractory to steroids ... Prognosis and treatment of polymyositis with particular reference to steroid resistant patients. ... Prognosis and treatment of polymyositis with particular reference to steroid resistant patients. ... Eight boys and six girls with polymyositis examined between 1967 and 1982 were studied. The mean age of disease onset was 5 ...
Following a twisting strain with immediate pain in the neck of a polymyositis patient we detail the analysis of a specific ... An Analysis of a Severe Neck Pain Experienced in a Polymyositis Patient R.M. Golding and L.G.F. Giles ... Following a twisting strain with immediate pain in the neck of a polymyositis patient we detail the analysis of a specific ...
Muscle inflammatory processes and their clinical manifestations in patients with polymyositis and dermatomyositis Czech version ... Lampa J, Nennesmo I, Einarsdottir H, Lundberg I. MRI guided muscle biopsy confirmed polymyositis diagnosis in a patient with ... Muscle inflammatory processes and their clinical manifestations in patients with polymyositis and dermatomyositis ... Muscle inflammatory processes and their clinical manifestations in patients with polymyositis and dermatomyositis ...
... miRNA may be associated with polymyositis/dermatomyositisCirculating plasma microRNA profiling in patients with polymyositis/ ... Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: ... dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositisAA11508953. ...
... a drastic change in this patient was observed with homeopathic treatment. ... Here is a case of female patient with progressive weakness of the limbs since childhood, ... Case-2: Difficult conditions like Polymyositis effectively treated with Homoeopathy. A (Patient Ref. No. S-2024), 14 years old ... Meet the doctor who has treated patients from. highest number of countries. Dr Rajesh Shah, MD, has treated patients from 180+ ...
In a 36-year-old patient with a severe polymyositis peripheral eosinophilia and abundant infiltration of muscle tissu ... In a 36-year-old patient with a severe polymyositis peripheral eosinophilia and abundant infiltration of muscle tissue by ... Idiopathic eosinophilic polymyositis is an uncommon disorder, first described in 1976. The eosinophilic granulocyte is ... Eosinophilic polymyositis was diagnosed. Treatment consisted of high dose prednisone, immunoglobulin and azathioprine, ...
Interstitial lung disease in patients with polymyositis and dermatomyositis - report of three cases. ... Interstitial lung disease in patients with polymyositis and dermatomyositis - report of three cases ... Polymyositis (PM) and dermatomyositis (DM) are connective tissue diseases (CTD) characterized by proximal muscle weakness along ... Polymyositis (PM) and dermatomyositis (DM) are connective tissue diseases (CTD) characterized by proximal muscle weakness along ...
Two specific types are polymyositis and dermatomyositis. Read about myositis symptoms and management. ... Patient Handouts Summary. Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or ... Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to ... Polymyositis: Can It Affect My Lungs? (Mayo Foundation for Medical Education and Research) Also in Spanish ...
Get information about polymyositis (PM) and dermatomyositis (DM) causes, symptoms, prognosis, medications, and treatment, plus ... Patient Comments. * Polymyositis - Effective Treatments Which treatment has been most effective for your polymyositis? ... Polymyositis is typically treated by rheumatologists. Others who can be involved in the care of patients with polymyositis ... Patients with polymyositis tend to have a higher risk for worse outcomes with older age, delay in cortisone treatment, cancer, ...
Clinically similar to polymyositis, dermatomyositis is an idiopathic, inflammatory myopathy associated with ... ... Polymyositis is an idiopathic inflammatory myopathy that causes symmetrical, proximal muscle weakness; elevated skeletal muscle ... Patient education. Patients with polymyositis should be educated early about the disease and should be provided with realistic ... In most patients, polymyositis responds well to treatment, although residual weakness occurs in approximately 30% of patients. ...
In CD4+ T cells, only two genes, ANKRD55 and S100B, were expressed significantly higher in patients with PM than in patients ... 176 genes were differentially expressed in patients with PM compared with patients with DM. Of these, 44 genes were expressed ... Our data strongly suggest that CD8+ T cells represent a major divergence between PM and DM patients compared with CD4+ T cells ... These alterations in the gene expression in T cells from PM and DM patients might advocate for distinct immune mechanisms in ...
Each tick mark corresponds to a time of patient censoring. The sex disparity was most pronounced among the polymyositis subset ... A total of 160 consecutive patients (77 with polymyositis and 83 with dermatomyositis) seen at the University of Michigan from ... Kaplan-Meier estimates for survival in polymyositis (PM) and dermatomyositis (DM) patients. Each tick mark corresponds to a ... Medsger TA, Robinson H, Masi AT: Factors affecting survivorship in polymyositis: a life-table study of 124 patients. Arthritis ...
N2 - A patient with active stable idiopathic polymyositis received a 4-week supervised right quadriceps and biceps isometric ... AB - A patient with active stable idiopathic polymyositis received a 4-week supervised right quadriceps and biceps isometric ... A patient with active stable idiopathic polymyositis received a 4-week supervised right quadriceps and biceps isometric ... abstract = "A patient with active stable idiopathic polymyositis received a 4-week supervised right quadriceps and biceps ...
  • MCTD is a specific subset of the broader category of rheumatic "overlap syndromes", a term used to describe when a patient has features of more than one classic inflammatory rheumatic disease. (rarediseases.org)
  • Among patients with MCTD, patterns of organ targeting have been reported that suggest disease subtypes. (rarediseases.org)
  • It can be diagnosed in a patient without any structural heart disease, however in the elderly, cardiovascular disease is often present. (credoweb.ro)
  • These measurements of myositis disease activity, although accurate, only capture specific aspects of disease activity, and do not necessarily objectively assess the patient-experienced consequence of myositis - namely reduced ability to carry out physical activities due to active muscle disease or irreversible muscle damage [ 8 ]. (biomedcentral.com)
  • Importantly, this study also identified that limitations of these physical activities are not wholly assessed in the HAQ-DI and Myositis Activities Profile (MAP) [ 10 ], two leading methods of patient-reported disease activity assessment - only 21% of reported disabilities were covered by the HAQ-DI and only 32% were covered by the MAP. (biomedcentral.com)
more